Clinical pathologic alterations associated with subcutaneous administration of recombinant human interleukin-4 to cynomolgus monkeys

Autor: Jack H. Dean, Joel B. Cornacoff, Kent A. Gossett, Thomas A. Barbolt, David J. Zelinger
Rok vydání: 1993
Předmět:
Male
Vasculitis
medicine.medical_specialty
Pathology
Lymphocytosis
040301 veterinary sciences
Lymphocyte
Injections
Subcutaneous
Biology
Toxicology
030226 pharmacology & pharmacy
Pathology and Forensic Medicine
0403 veterinary science
03 medical and health sciences
Hemoglobins
Leukocyte Count
0302 clinical medicine
Internal medicine
medicine
Eosinophilia
Animals
Humans
Hypoalbuminemia
Molecular Biology
Blood Coagulation
Interleukin 4
Hematology
Hyperplasia
04 agricultural and veterinary sciences
Cell Biology
Blood Proteins
Neoplasms
Experimental
Seminiferous Tubules
medicine.disease
Neutrophilia
Recombinant Proteins
Hypocholesterolemia
Macaca fascicularis
medicine.anatomical_structure
Hematocrit
Immunology
Erythrocyte Count
Prothrombin Time
Female
Interleukin-4
medicine.symptom
Atrophy
Granulocytes
Zdroj: Toxicologic pathology. 21(1)
ISSN: 0192-6233
Popis: Recombinant human interleukin 4 (rhuIL-4) is a candidate for the treatment of refractory cancer based on its potential to enhance immune function. Recombinant human IL-4 was administered subcutaneously at 0, 1, 5, or 25 μg/kg/day for 28 days with a 14-day recovery to male and female cynomolgus monkeys as part of the preclinical safety evaluation. Clinical pathologic changes related to treatment with rhuIL-4 were evidence of consumptive coagulopathy, erythrocyte fragmentation, lymphocytosis, and lymphocyte morphologic changes indicative of marked antigenic or mitogenic stimulation, mild eosinophilia and neutrophilia, hypoalbuminemia, hypocholesterolemia, and hypertriglyceridemia. Based on data obtained after the 14-day recovery period, the clinical pathologic changes associated with rhuIL-4 administration were considered to be reversible.
Databáze: OpenAIRE
Externí odkaz: